ClinicalTrials.gg
CompletedNCT01373164Updated May 16, 2018Results posted

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

A Phase 1/2 interventional study of Galunisertib and Gemcitabine in Neoplasms, Neoplasm Metastasis and Pancreatic Cancer, sponsored by Eli Lilly and Company. Completed at 24 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-16.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
170
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy

Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.

02

Conditions studied

  • Neoplasms
  • Neoplasm Metastasis
  • Pancreatic Cancer

Keywords

  • Neoplasms
  • Neoplasm Metastasis
  • Pancreatic Cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 170 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: For both Phase 1b and Phase 2 (unless specified in the following), patients are eligible to be included in the study only if they meet all of the following criteria:

For Phase 1b:

  • Have histological or cytological evidence of a diagnosis of cancer that is advanced and/or disease; that is to standard therapy and/or therapies known to provide clinical benefit or for which no standard therapy exists; and/or in which gemcitabine therapy at the proposed doses and schedule would be considered appropriate treatment for the metastatic disease (eg, pancreatic cancer)
  • Patients may have received prior chemotherapy, radiotherapy, cancer-related hormone therapy, or other therapy as treatment. There is no limit in the number of .

For Phase 1b and Phase 2:

  • Have or non-measurable disease, defined according to (RECIST)
  • Have given written prior to any study-specific procedures
  • Have adequate organ function including: Hematologic: (ANC) greater than or equal to 1.5 x 10\^9/L, greater than or equal to 100 x 10\^9/L, and greater than or equal to 9 g/dL. Hepatic: less than or equal to 1.5 times (ULN), and alkaline phosphatase (ALP), (AST), alanine aminotransferase (ALT)less than or equal to 2.5 times ULN. If the liver has tumor involvement, AST less than or equal to 5 times ULN and ALT less than or equal to 5 times ULN are acceptable. Patients may have endoscopic or radiologic stenting to treat biliary obstructions. If so, then bilirubin must return to less than or equal to 1.5 times ULN and ALP, AST, and ALT to less than or equal to 5 times ULN prior to enrollment. Renal: serum creatinine within normal limits, less than or equal to 1.5 times ULN.
  • Have a performance status of less than or equal to 2 on the (ECOG) scale
  • Patients must have recovered from any Grade 3/4 toxicities of previous therapies
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Prior radiation therapy for treatment of cancer is allowed to \<25% of the bone marrow, and patients must have recovered from the acute toxic effects of their treatment prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study entry.
  • Male and female patients with must use an approved method during and for 3 months after discontinuation of study treatment. Women of must have a negative beta-human chorionic gonadotropin (B-HCG) pregnancy test documented within 14 days prior to treatment. If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

For Phase 2:

  • Have histological or cytological diagnosis of adenocarcinoma of the pancreas that is locally advanced (Stage II, III) or metastatic (Stage IV) and not amenable to resection with curative intent. Patients with previous radical surgery for pancreatic cancer are eligible after progression is documented. If they received chemotherapy or chemoradiotherapy with gemcitabine, they can be enrolled if the treatment was completed 3 months before or longer
  • Tumor tissue or unstained slides are available from original or resection or other tumor biopsies
  • Patients may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreatic cancer. Adjuvant treatment must have finished at least 6 months before enrolling.

Exclusion Criteria: Patients will be excluded from the study if they meet any of the following criteria:

  • Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or unapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have moderate or severe cardiac disease:
  • Myocardial infarction within 6 months prior to study entry, unstable angina pectoris, (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension
  • Major abnormalities documented by echocardiography with Doppler (for example, moderate or severe heart valve function defect and/or (LVEF) \<50%, evaluation based on the institutional lower limit of normal)
  • Predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan-Syndrome, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by CT scan or MRI with contrast)
  • Are unable to swallow tablets or capsules
  • Are pregnant or breastfeeding
  • Have any significant medical illnesses that, in the investigator's opinion, cannot be adequately controlled with appropriate therapy or would compromise the patient's ability to tolerate this therapy
  • Have a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ), unless in complete remission and off of all therapy for that disease for a minimum of 3 years
  • Have active infection that would interfere with the study objectives or influence study compliance
  • Phase 2 only: Endocrine pancreatic tumors or ampullary cancer
  • Patients with acute or chronic leukemia or with any other disease likely to have a significant bone marrow infiltration (screening not required)
  • Have previously completed or withdrawn from this study or any other study investigating galunisertib or any other TGF-ß inhibitor
  • Have known allergy to galunisertib or gemcitabine or any ingredient of galunisertib or gemcitabine formulations
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Phase 1b: 80 mg Galunisertib + Gemcitabine

    Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Drug: Galunisertib · Drug: Gemcitabine

  • Experimental
    Phase 1b: 160 mg Galunisertib + Gemcitabine

    Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Drug: Galunisertib · Drug: Gemcitabine

  • Experimental
    Phase 1b: 300 mg Galunisertib + Gemcitabine

    Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Drug: Galunisertib · Drug: Gemcitabine

  • Experimental
    Phase 2: Recommended dose of Galunisertib + Gemcitabine

    Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Drug: Galunisertib · Drug: Gemcitabine

  • Experimental
    Phase 2: Placebo + Gemcitabine

    Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle). Gemcitabine at a dose of 1000 mg/m\^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks.

    Drug: Gemcitabine · Drug: Placebo

Interventions

  • Administered orally

    Also known as: LY2157299

  • Administered intravenously

    Also known as: Gemzar, LY188011

  • DrugPlacebo

    Administered orally

06

What researchers measure

Primary outcomes

  1. Phase 1b: Recommended Phase 2 Dose

    The recommended Phase 2 dose was the highest dose where less than 1/3 of participants experienced dose limiting toxicities (DLTs). The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b.

    Time frame: Time of first phase 1b dose until time of last phase 1b dose (up to 1 year)

  2. Phase 2: Overall Survival (OS)

    Overall survival is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date for a particular analysis, overall survival duration was censored for that analysis at the date of last prior contact.

    Time frame: Baseline to date of death from any cause (up to 2 years)

Secondary outcomes

  1. Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)

    AUC\[0-24h\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute. AUC0-infinity will take 48h and extrapolation beyond this in addition to earlier time points to be calculated. All mentioned time points are used to calculate the two AUCs.

    Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)

  2. Phase 1b: Pharmacokinetics: Maximum Plasma Drug Concentration at Steady State (Cmax,ss)

    Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.

    Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)

  3. Phase 1b: Number of Participants With Tumor Response

    Response was defined using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.

    Time frame: Baseline to end of Phase 1b (up to 1 year)

  4. Phase 2: Progression Free Survival (PFS)

    PFS is defined as the date of randomization to the first date of progression of disease or of death from any cause. For each participant who is not known to have died or to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, PFS will be censored at the date of last prior contact. PFS will be calculated and analyzed twice: (1) including clinical progressions of disease not based on lesion measurements, and (2) excluding clinical progressions. Progression Disease (PD) was defined as having at least a 25% increase in the sum of the longest diameter of target lesions.

    Time frame: Baseline to first date of progressive disease or death due to any cause (up to 2 years)

  5. Phase 2: Percentage Change From Baseline in Tumor Size (CTS)

    Change in tumor size is defined as the maximum percent change from baseline in the sum of target lesions. Change was assessed in each participant using radiographic imaging.

    Time frame: Baseline, end of Cycle 2 (up to 56 days)

  6. Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])

    Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

    Time frame: Baseline to measured progressive disease (up to 2 years)

  7. Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])

    AUC\[0-24\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute.

    Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)

  8. Phase 2: Population PK: Maximum Concentration (Cmax) of Galunisertib

    Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.

    Time frame: Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)

  9. Phase 2: Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) at Study Completion

    The BPI-SF Pain Severity Subscale was a participant-rated questionnaire that measured the severity of pain. Severity scores could have ranged from 0 (no pain) to 10 (pain as bad as you can imagine) for questions that included assessing average pain in the past 24 hours.

    Time frame: Baseline, study treatment completion (up to 1 year)

  10. Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up

    Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. The outcome measure is the median, minimum and maximum values from participants who had samples collected at baseline and at follow-up

    Time frame: Baseline, study treatment completion after first follow up visit (up to 1 year)

07

Results

Posted May 16, 2018

Participant flow

Participant flow — Overall Study
MilestonePhase 1b: 80 mg (Milligrams) Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Started54510452
Received at least one dose54510352
Completed5349250
Not completed011122
Withdrew: Lost to follow-up00120
Withdrew: Withdrawal by subject010102

Outcome measures

PrimaryPhase 1b: Recommended Phase 2 Dose

The recommended Phase 2 dose was the highest dose where less than 1/3 of participants experienced dose limiting toxicities (DLTs). The recommended dose was determined based on a review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b.

Time frame:
Time of first phase 1b dose until time of last phase 1b dose (up to 1 year)
Reported as:
Number · milligrams (mg)
Phase 1b: Recommended Phase 2 Dose
milligrams (mg)Phase 1b Participants
Phase 1b: Recommended Phase 2 Dose300
PrimaryPhase 2: Overall Survival (OS)

Overall survival is defined as the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cut-off date for a particular analysis, overall survival duration was censored for that analysis at the date of last prior contact.

Time frame:
Baseline to date of death from any cause (up to 2 years)
Reported as:
Median · Months
Phase 2: Overall Survival (OS)
MonthsPhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Phase 2: Overall Survival (OS)8.9 (7.3 to 11.1)7.1 (5.8 to 9.0)
Statistical analysis
  • Phase 2: 300 mg Galunisertib + Gemcitabine vs Phase 2: Placebo + Gemcitabine · Bayesian Analysis · Hazard ratio (hr): 0.794 · 95% CI 0.590 to 1.085This is a Credible Interval estimated from the Bayesian analysis.
SecondaryPhase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)

AUC\[0-24h\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute. AUC0-infinity will take 48h and extrapolation beyond this in addition to earlier time points to be calculated. All mentioned time points are used to calculate the two AUCs.

Time frame:
Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Phase 1b: Pharmacokinetics: Area Under the Concentration-Time Curve at Steady State From Time Zero to 24 Hours (AUC[0-24], ss) and Time Zero to Infinity (AUC[0-∞], ss)
nanogram*hour per milliliter (ng*h/mL)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + Gemcitabine
AUC(0-24)2530 ± 116NA ± NA9090 ± 27
AUC(0-∞)2740 ± 117NA ± NA10600 ± 10
SecondaryPhase 1b: Pharmacokinetics: Maximum Plasma Drug Concentration at Steady State (Cmax,ss)

Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.

Time frame:
Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Phase 1b: Pharmacokinetics: Maximum Plasma Drug Concentration at Steady State (Cmax,ss)
nanogram per milliliter (ng/mL)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + Gemcitabine
Phase 1b: Pharmacokinetics: Maximum Plasma Drug Concentration at Steady State (Cmax,ss)385 ± 101NA ± NA1050 ± 39
SecondaryPhase 1b: Number of Participants With Tumor Response

Response was defined using RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Complete Response (CR) was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) and normalization of tumor marker level of non-target lesions; Partial Response (PR) was defined as having at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD) was defined as having at least 20% increase in sum of longest diameter of target lesions and minimum 5 mm increase above nadir; Stable Disease (SD) was defined as small changes that did not meet above criteria.

Time frame:
Baseline to end of Phase 1b (up to 1 year)
Reported as:
Number · Participants
Phase 1b: Number of Participants With Tumor Response
ParticipantsPhase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + Gemcitabine
Progressive Disease (PD)312
Stable Disease (SD)122
Partial Response (PR)010
Non-Complete Response/Non-Progressive Disease (NC)001
Not Assessed (NA)100
SecondaryPhase 2: Progression Free Survival (PFS)

PFS is defined as the date of randomization to the first date of progression of disease or of death from any cause. For each participant who is not known to have died or to have had a progression of disease as of the data-inclusion cut-off date for a particular analysis, PFS will be censored at the date of last prior contact. PFS will be calculated and analyzed twice: (1) including clinical progressions of disease not based on lesion measurements, and (2) excluding clinical progressions. Progression Disease (PD) was defined as having at least a 25% increase in the sum of the longest diameter of target lesions.

Time frame:
Baseline to first date of progressive disease or death due to any cause (up to 2 years)
Reported as:
Median · Months
Phase 2: Progression Free Survival (PFS)
MonthsPhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Phase 2: Progression Free Survival (PFS)4.11 (2.66 to 5.42)2.86 (1.94 to 3.75)
SecondaryPhase 2: Percentage Change From Baseline in Tumor Size (CTS)

Change in tumor size is defined as the maximum percent change from baseline in the sum of target lesions. Change was assessed in each participant using radiographic imaging.

Time frame:
Baseline, end of Cycle 2 (up to 56 days)
Reported as:
Geometric mean · Percent change in tumor size
Phase 2: Percentage Change From Baseline in Tumor Size (CTS)
Percent change in tumor sizePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Independent Assessor 10.95 (0.90 to 1.01)0.92 (0.87 to 0.98)
Independent Assessor 21.03 (0.95 to 1.11)0.98 (0.92 to 1.05)
SecondaryPhase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])

Overall response rate is the best response of complete response (CR) or partial response (PR) as classified by the independent central review according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.

Time frame:
Baseline to measured progressive disease (up to 2 years)
Reported as:
Number · Percentage of Participants
Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])
Percentage of ParticipantsPhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Phase 2: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate[ORR])10.6 (5.4 to 18.1)3.8 (0.5 to 13.2)
SecondaryPhase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])

AUC\[0-24\] is a combined measure obtained from Day 14 at 0 hour (pre-dose), 0.5, 2,3, 6 hours post dose and morning doses from 24h and 48h to compute.

Time frame:
Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Reported as:
Mean · mg*h/L
Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])
mg*h/LPhase 2: 300 mg Galunisertib + Gemcitabine
Phase 2: Population Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC[0-24])5.56 (3.82 to 7.91)
SecondaryPhase 2: Population PK: Maximum Concentration (Cmax) of Galunisertib

Plasma samples for pharmacokinetic (PK) analysis were obtained on Day 14 at 0 hours (Pre-dose), 0.5, 2, 3, 6 hours post dose and morning doses from 24h and 48h. Cmax takes all time points post dose into account and one value is reported.

Time frame:
Cycle 1 Days 14 (predose; 0.5, 2, 3, and 6 hours post dose), 24h (Days 15) and 48h (Days 16)
Reported as:
Mean · ng/mL
Phase 2: Population PK: Maximum Concentration (Cmax) of Galunisertib
ng/mLPhase 2: 300 mg Galunisertib + Gemcitabine
Phase 2: Population PK: Maximum Concentration (Cmax) of Galunisertib904 (668 to 1194)
SecondaryPhase 2: Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) at Study Completion

The BPI-SF Pain Severity Subscale was a participant-rated questionnaire that measured the severity of pain. Severity scores could have ranged from 0 (no pain) to 10 (pain as bad as you can imagine) for questions that included assessing average pain in the past 24 hours.

Time frame:
Baseline, study treatment completion (up to 1 year)
Reported as:
Mean · Units on a scale
Phase 2: Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) at Study Completion
Units on a scalePhase 2: 300 mg Galunisertib + GemcitabinePlacebo+Gemcitabine
Phase 2: Change From Baseline in Brief Pain Inventory-short Form (BPI-sf) at Study Completion2.54 ± 2.531.50 ± 2.12
SecondaryPhase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up

Carbohydrate antigen 19-9 (CA 19-9) is a modified Lewis(a) blood group antigen, and has been used as a tumor marker. The outcome measure is the median, minimum and maximum values from participants who had samples collected at baseline and at follow-up

Time frame:
Baseline, study treatment completion after first follow up visit (up to 1 year)
Reported as:
Median · Units/Milliliter (U/mL)
Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up
Units/Milliliter (U/mL)Phase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Phase 2: Change From Baseline in Carbohydrate Antigen 19.9 (CA19-9) Level at First Study Completion Follow-up32.7 (-93.8 to 3636.3)-33.3 (-98.1 to 2460.9)

Adverse events

Collected over Up to 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b: 80 mg Galunisertib + Gemcitabine—1/5 (20%)5/5 (100%)
Phase 1b: 160 mg Galunisertib + Gemcitabine—1/4 (25%)4/4 (100%)
Phase 1b: 300 mg Galunisertib + Gemcitabine—2/5 (40%)5/5 (100%)
Phase 2: 300 mg Galunisertib + Gemcitabine—56/103 (54.4%)100/103 (97.1%)
Phase 2: Placebo + Gemcitabine—26/52 (50%)49/52 (94.2%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventPhase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
Abdominal painGastrointestinal disorders0/51/40/55/1031/52
Large intestinal obstructionGastrointestinal disorders1/50/40/50/1030/52
PyrexiaGeneral disorders0/50/41/54/1033/52
RhabdomyolysisMusculoskeletal and connective tissue disorders0/50/41/50/1030/52
Malignant ascitesNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/50/40/50/1030/52
Intestinal obstructionGastrointestinal disorders0/50/40/51/1033/52
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/50/40/55/1031/52
VomitingGastrointestinal disorders0/50/40/54/1032/52
CholangitisHepatobiliary disorders0/50/40/54/1032/52
NauseaGastrointestinal disorders0/50/40/52/1032/52
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPhase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + Gemcitabine
NauseaGastrointestinal disorders2/54/44/539/10317/52
ThrombocytopeniaBlood and lymphatic system disorders4/51/41/529/10313/52
AnaemiaBlood and lymphatic system disorders3/53/43/544/10328/52
VomitingGastrointestinal disorders3/53/43/527/10319/52
PyrexiaGeneral disorders1/53/42/538/10311/52
NeutropeniaBlood and lymphatic system disorders3/52/43/534/10317/52
AstheniaGeneral disorders0/51/43/536/10317/52
HypoalbuminaemiaMetabolism and nutrition disorders3/51/41/54/1031/52
HeadacheNervous system disorders3/51/41/56/1036/52
ConstipationGastrointestinal disorders2/52/41/530/10315/52

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + GemcitabineTotal
Mean63.2 ± 12.963.8 ± 9.056.6 ± 9.267.3 ± 8.266.3 ± 8.963.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + GemcitabineTotal
Female033462476
Male512572893
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + GemcitabineTotal
Hispanic or Latino001001
Not Hispanic or Latino544371868
Unknown or Not Reported0006634100
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + GemcitabineTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American200002
White3459550157
More than one race000000
Unknown or Not Reported0008210
Region of Enrollment
Region of Enrollment(Participants)Phase 1b: 80 mg Galunisertib + GemcitabinePhase 1b: 160 mg Galunisertib + GemcitabinePhase 1b: 300 mg Galunisertib + GemcitabinePhase 2: 300 mg Galunisertib + GemcitabinePhase 2: Placebo + GemcitabineTotal
Belgium000426
United States5217419
Italy000231033
France00021930
Germany000221436
Spain024261345
08

Study locations

24 sites
  • Florida Hospital Tampa HPG and Foregut Surgery
    Tampa, Florida 33613, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussel, 1000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liège, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Besancon, 25030, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Clermont-Ferrand, 63003, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13273, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montbéliard, 25250, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75674, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Frankfurt, 60596, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Friedrichshafen, 88045, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04103, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marburg, 35043, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Munich, 81925, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mönchengladbach, 41063, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Reutlingen, 72764, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bologna, 40138, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Verona, 37134, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28033, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pozuelo De Alarcon, 28223, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
09

References and documents

Publications

  • Smith CL, Thomas Z, Enas N, Thorn K, Lahn M, Benhadji K, Cleverly A. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs. Pharm Stat. 2020 May;19(3):276-290. doi: 10.1002/pst.1990. Epub 2020 Jan 5. PubMed 31903699 ↗
  • Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J. TGFbeta receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer. Cancer Chemother Pharmacol. 2019 May;83(5):975-991. doi: 10.1007/s00280-019-03807-4. Epub 2019 Mar 18. PubMed 30887178 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Nov 2015 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2018, 2 years 6 months after primary completion. A results delay was requested in Dec 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2011
First posted
Jun 14, 2011
Start
Jun 2011
Primary completionActual
Nov 2015
CompletionActual
Dec 2016
Results delay requested
Dec 23, 2015
Results first posted
May 16, 2018
Last update
May 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01373164
Responsible party
Sponsor
First posted
Jun 14, 2011
Start date
Jun 2011
Primary completion
Nov 2015
Completion
Dec 2016
Results posted
May 16, 2018
Last update
May 16, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY-2157299

Start the discussion